Author/Authors :
Aydın, Banu Dr. Sami Ulus Maternity and Children’s Health and DiseasesTraining and Research Hospital - Neonatology Unit, Turkey , Hoşağası, Nihan Dr. Sami Ulus Maternity and Children’s Health and Diseases TR Hospital - Neonatal Intensive Care Unit, Turkey , Zenciroğlu, Ayşegül Dr. Sami Ulus Maternity and Children’s Health and Diseases Training and Research Hospital - Neonatology Unit, Turkey , Karadağ, Nilgün Dr. Sami Ulus Maternity and Children’s Health and Diseases TR Hospital - Neonatal Intensive Care Unit, Turkey , Beken, Serdar Dr. Sami Ulus Maternity and Children’s Health and Diseases Training and Research Hospital - Neonatology Unit, Turkey , Dilli, Dilek Dr. Sami Ulus Maternity and Children’s Health and Diseases Training and Research Hospital - Neonatology Unit, Turkey , Okumuş, Nurullah Dr. Sami Ulus Maternity and Children’s Health and Diseases Training and Research Hospital - Neonatology Unit, Turkey
Abstract :
Objective: Viruses are demonstrated to be an uncommon etiologic agent of early and late pneumonia. In this study we aimed to investigate the safety and affectivity of oseltamivir use for viral pneumonia in newborns. Methods: This was a retrospective study conducted in a single tertiary neonatal intensive care unit between September 2009 and April 2013. Demographic, clinical and laboratory data before and after treatment, duration of hospitalization, time of clinical improvement were recorded. Results: During the study period, a total of 69 newborn cases who were treated by oseltamivir for H1N1 swine flu (n=12) or suspicious influenza (n=57) were evaluated. Mean birth weight and gestational age were 3100±601 grams and 37.9±1.8 weeks, respectively. On admission, median postnatal age was 20.6 (7-47) days. Oseltamivir, along with supportive care, was administered as 3.0 mg/kg/dose twice a day for 5 days according to the recommendations of Food and Drug Administration (FDA). The median time of initiation of oseltamivir was 2.3 days (1-4) after admission and the median hospitalization day was 10.4 days (5-22). No adverse effects associated with oseltamivir were observed and all patients were discharged after full recovery. Conclusion: Oseltamivir use in addition to supportive therapy seems to be safe and effective in newborns with severe viral pneumonia.
